Skip to main content

The role of nonsteroidal anti-inflammatory medications and exercise in the treatment of ankylosing spondylitis

Current Rheumatology Reports volume 8, pages 255–259 (2006)Cite this article

Abstract

Ankylosing spondylitis (AS) is a chronic systemic rheumatic disease that primarily affects the sacroiliac joints and spine. Even with the development of tumor necrosis factor-α inhibitors, which have revolutionized the treatment of this disease, the combination of nonsteroidal anti-inflammatory drugs (NSAIDs), physical therapy, and a life-long exercise program still form the first step in its management. Multiple clinical trials have addressed the efficacy and safety of both nonselective and selective NSAIDs. Gastrointestinal toxicity remains their major side effect, with increased concern about the potential of cardiovascular toxicity, especially with the selective cyclooxygenase-2 inhibitors. A specific set of recommendations has been proposed for the management of AS.

This is a preview of subscription content, access via your institution.

Access options

Buy single article

Instant access to the full article PDF.

43,34 €

Price includes VAT (Finland)
Tax calculation will be finalised during checkout.

References and Recommended Reading

  1. Khan MA: Update on spondyloarthropathies. Ann Intern Med 2002, 135:896–907.

    Google Scholar 

  2. Boulos P, Dougados M, Macleod SM, Hunsche E: Pharmacological treatment of ankylosing spondylitis: a systematic review. Drugs 2005, 65:2111–2127.

    PubMed  Article  CAS  Google Scholar 

  3. Zochling J, van der Heijde D, Dougados M, Braun J: Current evidence for the management of ankylosing spondylitis: a systematic literature review for the ASAS/EULAR management recommendations in ankylosing spondylitis. Ann Rheum Dis 2005, 65:423–432. The ASAS international working group, with funding from the EULAR, proposed ten recommendations for the management of AS management. These will be updated regularly.

    PubMed  Article  Google Scholar 

  4. Shekelle PG, Woolf SH, Eccles M, Grimshaw J: Clinical guidelines: developing guidelines. BMJ 1999, 318:593–596.

    PubMed  CAS  Google Scholar 

  5. Dougados M, Dijkmanns B, Khan MA: Conventional treatment for ankylosing spondylitis. Ann Rheum Dis 2002, 61:40–50.

    Google Scholar 

  6. Toussirot E, Wendling D: Recent progress in ankylosing spondylitis treatment. Expert Opin Pharmacother 2003, 4:1–12.

    PubMed  Article  CAS  Google Scholar 

  7. Dougados M, Revel M, Khan MA: Spondylarthropathy treatment: progress in medical treatment, physical therapy and rehabilitation. Baillieres Clin Rheumatol 1998, 12:717–736.

    PubMed  Article  CAS  Google Scholar 

  8. Dougados M, Béhier JM, Jolchine I, Calin A, et al.: Efficacy of celecoxib, a cyclooxygenase 2-specific inhibitor, in the treatment of ankylosing spondylitis: a six-week controlled study with comparison against placebo and against a conventional nonsteroidal antiinflammatory drug. Arthritis Rheum 2001, 44:180–185.

    PubMed  Article  CAS  Google Scholar 

  9. Chen J, Liu C: Methotrexate for ankylosing spondylitis. Cochrane Database Syst Rev 2004, 3:4524.

    Google Scholar 

  10. Van der Heijde D, Baraf HS, Ramos-Remus C, et al.:Arthritis Rheum. Evaluation of the efficacy of etoricoxib in ankylosing spondylitis: results of a fifty-two-week, randomized, controlled study. Arthritis Rheum 2005, 52:1205–1215.

    PubMed  Article  Google Scholar 

  11. Khan MA: Diclofenac in the treatment of ankylosing spondylitis: review of worldwide clinical experience and report of a double-blind comparison with indomethacin. Sem Arthritis Rheum 1985, 15:80–84.

    CAS  Google Scholar 

  12. Myklebust G: Comparison of naproxen and piroxicam in rheumatoid arthritis and Bechterew’s syndrome. A doubleblind parallel multicenter study. Tidsskr Nor Laegeforen 1986, 106:1485–1487.

    PubMed  CAS  Google Scholar 

  13. Nahir AM, Scharf Y: A comparative study of diclofenac and sulindac in ankylosing spondylitis. Rheumatol Rehabilit 1980, 19:193–198.

    Article  Google Scholar 

  14. Palferman TG, Webley M: A comparative study of nabumetone and indomethacin in ankylosing spondylitis. Eur J Rheumatol Inflamm 1991, 11:23–29.

    PubMed  CAS  Google Scholar 

  15. Wasner C, Britton MC, Kraines RG, et al.: Nonsteroidal anti-inflammatory agents in rheumatoid arthritis and ankylosing spondylitis. JAMA 1981, 246:2168–2172.

    PubMed  Article  CAS  Google Scholar 

  16. Zhang W, Doherty M, Arden N, et al.: EULAR evidence based recommendations for the management of hip osteoarthritis: report of a task force of the EULAR Standing Committee for International Clinical Studies Including Therapeutics (ESCISIT). Ann Rheum Dis 2005, 64:669–681.

    PubMed  Article  CAS  Google Scholar 

  17. Gossec L, van der Heijde D, Melian A, et al.: The efficacy of cyclooxygenase-2 inhibition by etoricoxib and naproxen on the axial manifestations of ankylosing spondylitis in the presence of peripheral arthritis. Ann Rheum Dis 2005, 64:1563–1567.

    PubMed  Article  CAS  Google Scholar 

  18. Graham DY, Agrawal NM, Campbell DR, et al.: Ulcer prevention in long-term users of nonsteroidal anti-inflammatory drugs: results of a double-blind, randomized, multicenter, active- and placebo-controlled study of misoprostol vs lansoprazole. Arch Intern Med 2002, 162:169–175.

    PubMed  Article  CAS  Google Scholar 

  19. Hooper L, Brown TJ, Elliott R, et al.: The effectivenes of five strategies for the prevention of gastrointestinal toxicity induced by non-steroidal anti-inflammatory drugs: systematic review. BMJ 2004, 329:948.

    PubMed  Article  CAS  Google Scholar 

  20. Garcia Rodriguez LA: Variability in risk of gastrointestinal complications with different nonsteroidal anti-inflammatory drugs. Am J Med 1998, 104:30S-34S.

    Article  Google Scholar 

  21. Lewis SC, Langman MJ, Laporte JR, et al.: Dose-response relationships between individual nonaspirin nonsteroidal anti-inflammatory drugs (NANSAIDs) and serious upper gastrointestinal bleeding: a meta-analysis based on individual patient data. Br J Clin Pharmacol 2002, 54:320–326.

    PubMed  Article  CAS  Google Scholar 

  22. Deeks JJ, Smith LA, Bradley MD: Efficacy, tolerability, and upper gastrointestinal safety of celecoxib for treatment of osteoarthritis and rheumatoid arthritis: systematic review of randomised controlled trials. BMJ 2002, 325:619–623.

    PubMed  Article  CAS  Google Scholar 

  23. Juni P, Nartey L, Reichenbach S, et al.: Risk of cardiovascular events and rofecoxib: cumulative meta-analysis. Lancet 2004, 364:2021–2029.

    PubMed  Article  CAS  Google Scholar 

  24. Graham DJ, Campen D, Hui R, et al.: Risk of acute myocardial infarction and sudden cardiac death in patients treated with cyclo-oxygenase 2 selective and non-selective non-steroidal anti-inflammatory drugs: nested case-control study. Lancet 2005, 365:475–481. This paper, based on data from Kaiser Permanente of California (Oakland, CA), has tried to clarify the controversy surrounding the question about whether high-dose rofecoxib increases or naproxen decreases the risk of serious coronary heart disease.

    PubMed  CAS  Google Scholar 

  25. Bolten WW: Problem of the atherothrombotic potential of non-steroidal anti-inflammatory drugs. Ann Rheum Dis 2006, 65:7–13. A comprehensive review of the risk of atherothromobotic disease associated with the use of NSAIDs, both selective and nonselective.

    PubMed  Article  CAS  Google Scholar 

  26. Bresalier RS, Sandler RS, Quan H, et al.: Cardiovascular events associated with Rofecoxib in a colorectal adenoma chemoprevention Trial. N Engl J Med 2005, 352:1092–1102. A multicenter, randomized clinical trial, with a large number of participants (n = 2586), showed that among patients with a history of colorectal adenomas, the use of rofecoxib was associated with an increased cardiovascular risk.

    PubMed  Article  CAS  Google Scholar 

  27. Solomon SD, McMurray JJ, Pfeffer MA, et al.: Cardiovascular risk associated with celecoxib in a clinical trial for colorectal adenoma prevention. N Engl J Med 2005, 352:1071–1080. A multicenter, randomized clinical trial with a large number of participants (n = 2035). Celecoxib use was associated with a dose-related increase in the composite end point of death from cardiovascular causes, myocardial infarction, stroke, or heart failure.

    PubMed  Article  CAS  Google Scholar 

  28. Nussmeier NA, Whelton AA, Brown MT, et al.: Complications of the COX-2 inhibitors parecoxib and valdecoxib after cardiac surgery. N Engl J Med 2005, 352:1081–1091. A multicenter, randomized clinical trial, with a large number of participants (n = 1671). The use of parecoxib and valdecoxib after coronary artery bypass graft was associated with an increased incidence of cardiovascular events.

    PubMed  Article  CAS  Google Scholar 

  29. Zochling J, Bohl-Buhler MH, Baraliakos X, et al.: Nonsteroidal anti-inflammatory drug use in ankylosing spondylitis-a population-based survey. Clin Rheumatol 2006, In press.

  30. Wanders A, van der Heijde D, Landewe R, et al.: Inhibition of radiographic progression in ankylosing spondylitis (AS) by continuous use of NSAIDs. Arthritis Rheum 2005, 52:1756–1765. A well done study, which is the first to show a possible disease-modifying effect of continuous NSAIDs therapy in a prospective manner.

    PubMed  Article  CAS  Google Scholar 

  31. Ward MM: Prospects for disease modification in ankylosing spondylitis: do nonsteroidal antiinflammatory drugs do more than treat symptoms? Arthritis and Rheum 2005, 52:1634–1636. An excellent, well-balanced review of the study by Wanders et al. [30•].

    Article  Google Scholar 

  32. Beck A, Salem K, Krischak G, et al.: Nonsteroidal antiin flammatory drugs (NSAIDs) in the perioperative phase in traumatology and orthopedics effects on bone healing. Oper Orthop Traumatol 2005, 17:569–578.

    PubMed  Article  Google Scholar 

  33. Mihai B, van der Linden S, de Bie R, Stucki G: Experts’ beliefs on physiotherapy for patients with ankylosing spondylitis and assessment of their knowledge on published evidence in the field. Results of a questionnaire among international ASAS members. Eura Medicophys 2005, 41:149–153.

    PubMed  CAS  Google Scholar 

  34. Dagfinrud H, Kvien TK, Hagen KB: The Cochrane review of physiotherapy interventions for ankylosing spondylitis. J Rheumatol 2005, 32:1899–1906. This is an excellent update of the Cochrane review on the effectiveness of physiotherapy interventions in the management of AS.

    PubMed  Google Scholar 

  35. van der Linden S, van Tubergen S, Hidding A: Physiotherapy in ankylosing spondylitis: what is the evidence? Clin Exp Rheumatol 2002, 20:S60-S64.

    PubMed  Google Scholar 

  36. Kraag G, Stokes B, Groh J, et al.: The effects of comprehensive home physiotherapy and supervision on patients with ankylosing spondylitis-a randomized controlled trial. J Rheumatol 1990, 17:228–233.

    PubMed  CAS  Google Scholar 

  37. Kraag G, Stokes B, Groh J, et al.: The effects of comprehensive home physiotherapy and supervision on patients with ankylosing spondylitis—an 8-month followup. J Rheumatol 1994, 21:261–263.

    PubMed  CAS  Google Scholar 

  38. Hidding A, Van Der LS, Boers M, et al.: Is group physical therapy superior to individualized therapy in ankylosing spondylitis? A randomized controlled trial. Arthritis Care Res 1993, 6:117–125.

    PubMed  Article  CAS  Google Scholar 

  39. Helliwell PS, Abbott CA, Chamberlain MA: A randomised trial of three different physiotherapy regimes in ankylosing spondylitis. Physiotherapy 1996, 82:85–90.

    Article  Google Scholar 

  40. Analay Y, Ozcan E, Karan A, et al.: The effectiveness of intensive group exercise on patients with ankylosing spondylitis. Clinical Rehabilitation 2003, 17:631–636.

    PubMed  Article  Google Scholar 

  41. Sweeney S, Taylor G, Calin A: The effect of a home based exercise intervention package on outcome in ankylosing spondylitis: a randomized controlled trial. Journal of Rheumatology 2002, 29:763–766.

    PubMed  Google Scholar 

  42. Lim HJ, Moon YI, Lee MS: Effects of home-based daily exercise therapy on joint mobility, daily activity, pain, and depression in patients with ankylosing spondylitis. Rheumatol Int 2005, 25:225–29.

    PubMed  Article  Google Scholar 

  43. Bulstrode SJ, Barefoot J, Harrison RA, Clarke AK: The role of passive stretching in the treatment of ankylosing spondylitis. Br J Rheumatol. 1987, 26:40–42.

    PubMed  Article  CAS  Google Scholar 

  44. van Tubergen A, Landewe R, van der Heijde D, et al.:Combined spa-exercise therapy is effective in patients with ankylosing spondylitis: a randomized controlled trial. Arthritis Rheum 2001, 45:430–438.

    PubMed  Article  Google Scholar 

  45. van Tubergen A, Boonen A, Landewe R, et al.: Cost effectiveness of combined spa-exercise therapy in ankylosing spondylitis: a randomized controlled trial. Arthritis Rheum 2002, 47:459–467.

    PubMed  Article  Google Scholar 

  46. Heikkilä S, Viitanen JV, Kautiainen H, Kauppi M: Sensitivity to change of mobility tests; effect of short term intensive physiotherapy and exercise on spinal, hip, and shoulder measurements in spondyloarthropathy. J Rheumatol 2000, 27:1251–1256.

    PubMed  Google Scholar 

  47. Uhrin Z, Kuzis S, Ward MM: Exercise and changes in health status in patients with ankylosing spondylitis. Arch Intern Med 2000, 160:2969–2975.

    PubMed  Article  CAS  Google Scholar 

  48. Lim HJ, Lee MS, Lim HS: Exercise, pain, perceived family support, and quality of life in Korean patients with ankylosing spondylitis. Psychol Rep 2005, 96:3–8.

    PubMed  Article  Google Scholar 

  49. Fernandez-de-Las-Penas C, Alonso-Blanco C, Morales- Cabezas M, Miangolarra-Page JC: Two exercise interventions for the management of patients with ankylosing spondylitis: a randomized controlled trial. Am J Phys Med Rehabil 2005, 84:407–419.

    PubMed  Article  Google Scholar 

Download references

Author information

Affiliations

  1. MetroHealth Medical Center, Division of Rheumatology, Case Western Reserve University, 2500 MetroHealth Drive, 44109, Cleveland, OH, USA

    Mazen Elyan MD

Authors
  1. Mazen Elyan MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Muhammad Asim Khan MD, MACP
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Mazen Elyan MD.

Rights and permissions

Reprints and Permissions

About this article

Cite this article

Elyan, M., Khan, M.A. The role of nonsteroidal anti-inflammatory medications and exercise in the treatment of ankylosing spondylitis. Curr Rheumatol Rep 8, 255–259 (2006). https://doi.org/10.1007/s11926-006-0005-7

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11926-006-0005-7

Keywords

  • Ankylose Spondylitis
  • Celecoxib
  • Spondylitis
  • Rheumatol
  • Rofecoxib